Junshi Biosciences Reports the CHMP’s Positive Opinion of Loqtorzi (Toripalimab) Across Two Indications
Shots:
- The CHMP has granted positive opinion to 1L Loqtorzi with cisplatin & gemcitabine for recurrent, metastatic NPC as well as with cisplatin & paclitaxel for unresectable advanced, recurrent or metastatic ESCC; valid across the EU plus Iceland & Norway
- The opinions for NPC & ESCC were supported by P-III (JUPITER-02 & JUPITER-06) trials, respectively; JUPITER-02 results were highlighted at ASCO 2021 & published in Nature Medicine & JAMA, with JUPITER-06 results featured at ESMO 2021 & published in Cancer Cell & Journal of Clinical Oncology
- Toripalimab, an anti-PD-1 mAb, works by blocking PD-1 interactions with PD-L1 & PD-L2 ligands to improve endocytosis function
Ref: Globenewswire | Image: Coherus
Related News:- Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (NPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
